In The Lancet Oncology, Jyoti Bajpai and colleagues1 reported that olanzapine 2·5 mg should be considered as a new standard of care for antiemetic agents in patients receiving highly emetogenic chemotherapy.
[Correspondence] Olanzapine for chemotherapy-induced nausea and vomiting control
For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –
LATEST
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy